ESR1 and cancer: Approximately 60% of BRCA1-associated breast cancers are triple negative (TNBC), i.e., negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2); these are very aggressive and high-grade cancers with a poor prognosis (6, 7).